Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA
NCT06591312 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900
Last updated 2024-09-19
Summary
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.
Conditions
Interventions
- DRUG
-
Ticagrelor 90 MG
The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
- DRUG
-
Clopidogrel
The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Sponsors & Collaborators
-
Kafrelsheikh University
lead OTHER
Principal Investigators
-
mohamed G. Zeinhom, MD · neurology department kafr el-sheikh university
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-01
- Primary Completion
- 2024-09-10
- Completion
- 2024-09-25
- FDA Drug
- Yes
Countries
- Egypt
Study Locations
More Related Trials
-
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
NCT02144831 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
NCT05476991 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk
NCT02960126 ·Status: UNKNOWN ·Phase: PHASE3
-
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
NCT01225562 ·Status: COMPLETED ·Phase: PHASE3
-
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets
NCT03005704 ·Status: UNKNOWN ·Phase: NA
-
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
NCT04484259 ·Status: COMPLETED ·Phase: PHASE4
-
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
NCT04945616 ·Status: COMPLETED ·Phase: PHASE1
-
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
NCT02270242 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
NCT04962451 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
NCT05093790 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man
NCT02120092 ·Status: COMPLETED ·Phase: PHASE2
-
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
NCT01744288 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
NCT02325466 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
NCT05986968 ·Status: RECRUITING ·Phase: NA
-
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
NCT04739384 ·Status: COMPLETED ·Phase: PHASE3
-
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
NCT04240834 ·Status: RECRUITING ·Phase: PHASE4
-
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
NCT01212302 ·Status: COMPLETED ·Phase: NA
-
Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"
NCT02206815 ·Status: COMPLETED ·Phase: PHASE4
-
Triple vs. Dual Therapy
NCT02080858 ·Status: COMPLETED ·Phase: PHASE1
-
Antithrombotic Triple Therapy in Humans
NCT01812200 ·Status: COMPLETED ·Phase: PHASE4
-
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
NCT01994720 ·Status: COMPLETED ·Phase: PHASE3
-
Reversal of the Anti-platelet Effects of Ticagrelor
NCT02383771 ·Status: COMPLETED ·Phase: PHASE4
-
Ticagrelor and Peripheral Arterial Disease
NCT02407314 ·Status: TERMINATED ·Phase: PHASE4
-
Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
NCT02219412 ·Status: COMPLETED ·Phase: PHASE4
-
Reversing Ticagrelor's Effects With Fresh Platelets
NCT02201394 ·Status: COMPLETED ·Phase: PHASE4